Price to Sales (P/S)
since 2012
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Operating Profit Margin since 2012
- Current Ratio since 2012
- Price to Earnings (P/E) since 2012
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
AbbVie Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Net revenues1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2013 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of AbbVie Inc. Annual Report.
- Share Price
- The share price demonstrated significant volatility over the period analyzed. Starting at $38.50 in March 2013, it generally increased, reaching a notable peak at $118.60 in February 2018. Following this peak, there was a pronounced decline to $79.41 in February 2019. Subsequently, the share price exhibited a steady upward trajectory, culminating at $192.87 in February 2025, the highest value in the series.
- Sales per Share
- Sales per share showed a consistent and generally upward trend across the years. From $11.65 in March 2013, the metric increased steadily, reaching $32.81 in February 2023. A slight decline appeared in February 2024 to $30.75, but it rose again to $31.91 by February 2025. This pattern suggests growing sales performance with minor fluctuations.
- Price-to-Sales (P/S) Ratio
- The P/S ratio exhibited high variability during the period. It began at 3.30 in March 2013 and spiked sharply to 6.67 in February 2018, coinciding with the peak share price. This value then dropped to 3.58 by February 2019, reflecting the share price decline. Subsequently, the ratio gradually increased once more, reaching 6.04 in February 2025. The fluctuations in P/S indicate changing market valuations relative to sales, including periods of high investor optimism and corrections.
- Overall Observations
- The share price and P/S ratio show volatile behavior, marked by significant peaks and troughs, while sales per share demonstrate a stable growth trend. The disconnect between share price and sales at certain points, such as the 2018 peak in P/S ratio and share price, indicates varying market sentiment or external factors influencing valuation beyond fundamental sales growth.
Comparison to Competitors
AbbVie Inc., P/S, long-term trends, comparison to competitors
| AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | ||||||||||||
| Feb 20, 2024 | ||||||||||||
| Feb 17, 2023 | ||||||||||||
| Feb 18, 2022 | ||||||||||||
| Feb 19, 2021 | ||||||||||||
| Feb 21, 2020 | ||||||||||||
| Feb 27, 2019 | ||||||||||||
| Feb 16, 2018 | ||||||||||||
| Feb 17, 2017 | ||||||||||||
| Feb 19, 2016 | ||||||||||||
| Feb 20, 2015 | ||||||||||||
| Feb 21, 2014 | ||||||||||||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
AbbVie Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| AbbVie Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 14, 2025 | ||
| Feb 20, 2024 | ||
| Feb 17, 2023 | ||
| Feb 18, 2022 | ||
| Feb 19, 2021 | ||
| Feb 21, 2020 | ||
| Feb 27, 2019 | ||
| Feb 16, 2018 | ||
| Feb 17, 2017 | ||
| Feb 19, 2016 | ||
| Feb 20, 2015 | ||
| Feb 21, 2014 | ||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
AbbVie Inc., P/S, long-term trends, comparison to industry (health care)
| AbbVie Inc. | Health Care | |
|---|---|---|
| Feb 14, 2025 | ||
| Feb 20, 2024 | ||
| Feb 17, 2023 | ||
| Feb 18, 2022 | ||
| Feb 19, 2021 | ||
| Feb 21, 2020 | ||
| Feb 27, 2019 | ||
| Feb 16, 2018 | ||
| Feb 17, 2017 | ||
| Feb 19, 2016 | ||
| Feb 20, 2015 | ||
| Feb 21, 2014 | ||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).